ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565

In Novartis’s pipeline, Anti-CD19, Anti-CD2, Anti-CD3. Its studies are mostly in Lymphoma, B-Cell · Lupus Erythematosus, Systemic · Arthritis, Rheumatoid, led by Novartis.

Drug pageAnti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 1, since May 25, 20223 company-led studies, 3 open or runningNext primary completion: Jan 4, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis33 open or runningphase 1since May 25, 2022May 25, 2022Jan 4, 2027phase 1 · NCT05397496
  • Named in Novartis’s own pipeline as PIT565, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 25, 2022First study: phase 1 study in Lymphoma, B-CellFirst studyNCT05397496 · 61 enrolled · United States, Belgium, China and more
  2. Mar 22, 2024Phase 1 study in Lupus Erythematosus, SystemicNCT06335979 · 54 enrolled · China, Germany, Hungary and more
  3. Jun 11, 2025Phase 1 study in Arthritis, RheumatoidNCT07029555 · 57 enrolled · Argentina, Bulgaria, China and more

Ahead

  1. Jan 4, 2027Primary completion: phase 1 study in Lymphoma, B-CellNCT05397496
  2. Nov 17, 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06335979
  3. May 15, 2028Primary completion: phase 1 study in Arthritis, RheumatoidNCT07029555

TargetBeta

“Anti-CD19, Anti-CD2, Anti-CD3”the company's pipeline, read by Claude · source
“A trispecific T-cell engager and antibody targeting the tumor-associated antigen (TAA) CD19, the T-cell surface antigen CD3, and the T-cell co-stimulatory receptor CD2, ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07029555Arthritis, Rheumatoid · Argentina, Bulgaria, China and more1Active, not recruitingMay 15, 202857
NCT06335979Lupus Erythematosus, Systemic · China, Germany, Hungary and more1Active, not recruitingNov 17, 202754
NCT05397496Lymphoma, B-Cell · United States, Belgium, China and more1Active, not recruitingJan 4, 202761

How it is read

Names in the registry

  • “PIT565”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.